Cristin-person-ID: 381016
Person

Fredrik Hellem Schjesvold

  • Stilling:
    Forsker
    ved Avdeling for blodsykdommer ved Universitetet i Oslo
  • Stilling:
    Cand.med.stipendiater
    ved Avdeling for immunologi og transfusjonmedisin ved Oslo universitetssykehus HF

Resultater Resultater

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.

Terpos, Evangelos; Zamagni, Elena; Lentzsch, Suzanne; Drake, Matthew; García-Sanz, Ramón; Abildgaard, Niels; Ntanasis-Stathopoulos, Ioannis; Schjesvold, Fredrik H; de la Rubia, Javier; Kyriakou, Charalampia mfl.. 2021, The Lancet Oncology. USA, OUH, VUA, CUitCoNY, UOA, MAYO, UCV, SPANIA, OUS, ROSWELL, UCLH, FRANKRIKE, HMS, UIO, UdSdB, UdNVitenskapelig oversiktsartikkel/review

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Dimopoulos, Meletios A.; Moreau, Philippe; Terpos, Evangelos; Mateos, Maria-Victoria; Zweegman, Sonja; Cook, G.; Delforge, Michel; Hájek, R.; Schjesvold, Fredrik H; Cavo, Michele mfl.. 2021, Annals of Oncology. UNIW, VUA, UOA, UdSdT, SPANIA, OUS, TSJEKKIA, FRANKRIKE, UZLEUVEN, UoL, UNILILLE, SVEITS, UIO, HUH, NEDERLAND, UdSdBVitenskapelig artikkel

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

Moreau, Philippe; Kumar, Shaji; San Miguel, Jesús; Davies, Faith E.; Zamagni, Elena; Bahlis, Nizar; Ludwig, Heinz; Mikhael, Joseph; Terpos, Evangelos; Schjesvold, Fredrik H. mfl.. 2021, The Lancet Oncology. UdP, HÊ, UdS, Ou, MAYO, FREIBURG, UoNMC, UH, UNILILLE, AMC, UCALGARY, EMC, UNIW, PORTUGAL, UoSF, HCB, DANAFARBER, MELB, LEEDSTH, OUS, UJwK, EU, INSERM, KINA, UKHE, UIO, AÜ, UoCSF, UdSdB, VGR, KAROLINSKA, NAVARRA, STOLAV, HUMV, AKHWIEN, HUH, AMIKMWP, USA, SU, VUA, CUitCoNY, UOA, BRASIL, RTSUONJ, UoAaB, KU, NYU, MGH, SSN, NUoS, CS, UFdRdJ, TYRKIA, PETERMAC, SVEITS, ICR, MCoW, TGEN, UdlR, UdN, UCLVitenskapelig oversiktsartikkel/review

Melflufen for relapsed and refractory multiple myeloma.

Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman; Hassoun, Hani; Rodriguez-Otero, Paula; Paner, Agne; Schjesvold, Fredrik H; Gullbo, Joachim; Richardson, Paul. 2020, Expert Opinion on Investigational Drugs. UdP, Uu, RU, MSKCC, Ou, IGTP, UdSdT, DANAFARBER, UIO, OUS, UdN, HMSVitenskapelig artikkel

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

Laubach, Jacob P.; Schjesvold, Fredrik H; Mariz, Mário; Dimopoulos, Meletios A.; Lech-Maranda, Ewa; Spicka, Ivan; Hungria, Vania T.M.; Shelekhova, Tatiana; Abdo, Andre; Jacobasch, Lutz mfl.. 2020, The Lancet Oncology. DE, IDIBAPS, Ou, MONASH, MAYO, IPO, UB, POLEN, SGMU, TYSKLAND, BIC, CUN, UdSP, UOA, BRASIL, DANAFARBER, HOT, OUS, HMS, EU, CU, UKVP, AMIPÒWW, UIO, AÜ, MSSoMotCUoVitenskapelig artikkel
1 - 5 av 26 | Neste | Siste »